Both whole blood (WB) and component therapy (CT) are used for hemostatic resuscitation in injured children. We hypothesize that early WB transfusion c...

Previous studies suggest that in children with hemorrhagic shock following injury, prehospital blood transfusion improves survival. Quantifying and un...

Myeloproliferative neoplasms (MPNs), encompassing polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are hematol...

Investigator-led research and quality improvement initiatives have led to important improvements in the diagnostic assessment of platelet function dis...

Current CALR mutation screening in myeloproliferative neoplasms (MPNs) faces a trade-off between coverage and cost: allele-specific qPCR and fragment ...

Chimeric antigen receptor (CAR)-T cells are engineered T cells that are genetically modified to express a synthetic receptor capable of recognizing specific antigens on the surface of target cells, leading to their elimination. To date, CAR-T cell therapy has demonstrated remarkable efficacy in relapsed and refractory B cell malignancies, with seven CAR-T products approved by the FDA1. Although autologous CAR-T therapy has provided unprecedented clinical benefits for many patients, its efficacy varies significantly across individuals with different hematological malignancies.

Chimeric antigen receptor (CAR)-T cells are engineered T cells that are genetically modified to express a synthetic receptor capable of recognizing specific antigens on the surface of target cells, leading to their elimination. To date, CAR-T cell therapy has demonstrated remarkable efficacy in relapsed and refractory B cell malignancies, with seven CAR-T products approved by the FDA1. Although autologous CAR-T therapy has provided unprecedented clinical benefits for many patients, its efficacy varies significantly across individuals with different hematological malignancies.